Versicor (VERS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Versicor (VERS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	11/17/2004 2:12:20 PM
	Read Replies (1) of 83

17-Nov-2004 Regulation FD Disclosure Item 7.01 Regulation FD Disclosure. In meetings yesterday, Vicuron Pharmaceuticals Inc. (the "Company") discussed the following information: (1) the U.S. Food and Drug Administration (the "FDA") has granted "Fast Track" status for dalbavancin in complicated skin and soft tissue infections; (2) the Company's intention to file a new drug application ("NDA") for dalbavancin only for complicated skin and soft tissue infections; and (3) the Company's belief that the need to address complicated infections may increase the possibility that the FDA may conduct an expedited review of the contemplated NDA filing. The Company also expressed its belief that its lead antibacterial product could ultimately need a sales force of up to 125 people. The Company is furnishing promptly this Current Report on Form 8-K solely to satisfy the requirements of Regulation FD.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next